Decoy Therapeutics (DCOY) Free Cash Flow (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Free Cash Flow of -$2.9 million for Q1 2026, down 144.5% year-over-year from $6.5 million in Q1 2025, and down 154.23% quarter-over-quarter from -$1.1 million in Q4 2025.
Decoy Therapeutics (DCOY) Free Cash Flow (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Free Cash Flow for 12 consecutive years, with -$2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 144.5% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$6.5 million (down 50.12% YoY), while the FY2025 annual figure was -$5.4 million, down 19.42% from the prior year.
- Free Cash Flow slipped to -$2.9 million in Q1 2026 per DCOY's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$742518.0 in Q4 2024 and bottomed at -$5.7 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$2.5 million across 5 years, with a median of -$1.6 million in 2025.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 262.9% — and 2024, when it jumped 75.72%.
- Decoy Therapeutics' Free Cash Flow stood at -$4.7 million in 2022, then jumped by 67.94% to -$1.5 million in 2023, then jumped by 50.87% to -$742518.0 in 2024, then plunged by 53.06% to -$1.1 million in 2025, then plunged by 154.23% to -$2.9 million in 2026.
- Business Quant data shows DCOY's Free Cash Flow at -$2.9 million in Q1 2026, -$1.1 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.65 Mn |
| Jun 30, 2026 | -2.65 Mn |
| Mar 31, 2026 | -2.89 Mn |
| Mar 31, 2026 | -2.89 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Dec 31, 2025 | -1.14 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -862,297.00 |
| Jun 30, 2025 | -862,297.00 |
| Mar 31, 2025 | -1.18 Mn |
| Mar 31, 2025 | -1.18 Mn |
| Dec 31, 2024 | -742,518.00 |
| Dec 31, 2024 | -742,518.00 |
| Sep 30, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | -1.35 Mn |
| Mar 31, 2024 | -1.35 Mn |